Loading...
Loading...
Watson Pharmaceuticals, Inc.
WPI today announced that it has launched an authorized generic version of Xopenex (levalbuterol HCl) Inhalation Solution as part of an agreement with Sunovion Pharmaceuticals, Inc. Watson began shipping the product today. Xopenex Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in